WO2008140565A3 - Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis - Google Patents
Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis Download PDFInfo
- Publication number
- WO2008140565A3 WO2008140565A3 PCT/US2007/084140 US2007084140W WO2008140565A3 WO 2008140565 A3 WO2008140565 A3 WO 2008140565A3 US 2007084140 W US2007084140 W US 2007084140W WO 2008140565 A3 WO2008140565 A3 WO 2008140565A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antagonists
- necrosis factor
- factor receptor
- polypeptides
- tumor necrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Novel tumor necrosis factor receptor (TNFR) polypeptides, polynucleotides encoding the polypeptides, antibodies and related compositions and methods are disclosed. The polypeptides may be used for detecting ligand, as well as agonists and antagonists. The polypeptides, polynucleotides and antibodies may also be used in methods that modulate tumor growth, metastasis, and immunity such as separating resting from stimulated immune cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86486406P | 2006-11-08 | 2006-11-08 | |
US60/864,864 | 2006-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008140565A2 WO2008140565A2 (en) | 2008-11-20 |
WO2008140565A3 true WO2008140565A3 (en) | 2009-06-11 |
Family
ID=40002800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/084140 WO2008140565A2 (en) | 2006-11-08 | 2007-11-08 | Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008140565A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056908B2 (en) | 2007-08-03 | 2015-06-16 | Abbvie Biotherapeutics Inc. | Therapeutic use of anti-tweak receptor antibodies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037865A2 (en) * | 2003-10-16 | 2005-04-28 | Zymogenetics, Inc. | Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR |
-
2007
- 2007-11-08 WO PCT/US2007/084140 patent/WO2008140565A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037865A2 (en) * | 2003-10-16 | 2005-04-28 | Zymogenetics, Inc. | Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR |
Non-Patent Citations (2)
Title |
---|
AGGARWAL B B ET AL: "TNF blockade: An inflammatory issue", 56TH INTERNATIONAL WORKSHOP ON CYTOKINES AS POTENTIAL THERAPEUTIC TARGETS FOR INFLAMMATORY SKIN DISE; SAN FRANCISCO, CA, USA; NOVEMBER 17 -19, 2004,, 1 January 2006 (2006-01-01), pages 161 - 186, XP009115475, ISBN: 978-3-540-25427-0 * |
FIDALGO A ET AL: "Etanercept for psoriasis: Two case reports", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, BIOSCIENCE EDIPRINT, GENEVA, CH, vol. 25, no. 4, 1 January 2005 (2005-01-01), pages 159 - 163, XP009115472, ISSN: 0251-1649 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008140565A2 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005080429A3 (en) | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies | |
TW200631594A (en) | Toll like receptor 3 antagonists, methods and uses | |
IL245462A0 (en) | Humanized anti-cmet antagonists | |
IL166659A0 (en) | Nogo receptor antagonists | |
MX2009002571A (en) | Anti-activin a antibodies and uses thereof. | |
EP2526968A3 (en) | Nogo receptor antagonists | |
PH12012501006A1 (en) | Compositions and methods relating to anti-igf-1 receptor antibodies | |
WO2009005809A3 (en) | Compositions and methods for treating and diagnosing cancer | |
EA201500316A1 (en) | Antagonists of toll-like receptor 3 | |
IL163067A (en) | Isolated heterodimeric cytokine receptor | |
MY156315A (en) | Anti-vegf antibodies | |
WO2007051164A8 (en) | Toll like receptor 3 modulators, methods and uses | |
WO2006002102A3 (en) | Spirocyclic compounds useful as modulators of nuclear hormone receptor function | |
WO2007059190A3 (en) | Compositions of and methods of using stabilized psma dimers | |
MXPA05011409A (en) | Compositions and methods for the therapy of inflammatory bowel disease. | |
PL380274A1 (en) | Nogo receptor antagonists | |
GB2445638A (en) | Granular solid wax particle | |
EA201171307A1 (en) | Antagonists of toll-like receptor 3 | |
WO2005065339A3 (en) | Cell cycle genes and related methods of using | |
WO2003018798A3 (en) | G-protein coupled receptor and dna sequences thereof | |
WO2008140565A3 (en) | Use of tumor necrosis factor receptor 14 antagonists for treating psoriasis | |
WO2005037865A3 (en) | Ztnfr14, A TUMOR NECROSIS FACTOR RECEPTOR | |
WO2003044162A3 (en) | Genes encoding g-protein coupled receptors and methods of use therefor | |
EP1212340A4 (en) | 29 human cancer associated proteins | |
WO2006013462A3 (en) | Growth factors nsg28, nsg30, and nsg32 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07874261 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07874261 Country of ref document: EP Kind code of ref document: A2 |